Procter & Gamble’s stock up after earnings beat estimates

Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.

Procter & Gamble Co.’ stock PG, +0.13% rose 0.9% premarket Wednesday, after the consumer goods giant beat estimates for its fiscal first quarter and backed its fiscal 2024 guidance. The Cincinnati-based parent of brands including Charmin, Crest and Pampers, posed net income of $4.521 billion, or $1.83 a share, for the quarter to Sept. 30, up from $3.963 billion, or $1.57 a share, in the year-earlier period. Adjusted per-share earnings also came to $1.83, ahead of the $1.72 FactSet consensus.

Sales were boosted by another rise in prices of 7%, “We delivered very strong results in the first quarter of fiscal year 2024, putting us on track to deliver towards the higher end of our fiscal year guidance ranges for organic sales and core EPS growth,” said Jon Moeller, chief executive, in a statement. The company now expects full-year sales to grow 2% to 4% and still expects EPS of $6.25 to $6.43. The FactSet consensus is for EPS of $6.39.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

MarketWatch /  🏆 3. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

Church & Dwight, Procter & Gamble Are Staples Stock PicksWells Fargo analyst Chris Carey likes Church & Dwight, Procter & Gamble, and Keurig Dr Pepper stock.
Les mer »

3 Stock Picks in the Crumbling Staples SectorWells Fargo analyst Chris Carey likes Church & Dwight, Procter & Gamble, and Keurig Dr Pepper stock.
Les mer »

Best Buy to start offering early Black Friday deals on Oct. 30Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Les mer »

Amazon, Booking, Expedia and Tripadvisor form coalition to combat fake online reviewsCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Les mer »

Evelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goalCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Les mer »